Starting a pharmaceutical manufacturing unit is a capital-intensive, highly regulated and technically demanding business.

A successful pharmaceutical factory requires much more than:

• Land
• Building
• Tablet or syrup machinery
• Manufacturing licence

A modern project must integrate:

• Regulatory strategy
• Good Manufacturing Practices
• Pharmaceutical Quality System
• Quality Risk Management
• Product selection
• Manufacturing capacity
• HVAC
• Pharmaceutical water
• Quality-control laboratory
• Validation
• Qualified technical staff
• Working capital
• Marketing strategy
• Distribution
• Product registrations
• Pharmacovigilance
• Recall and complaint systems

Therefore, a pharmaceutical project should begin with a Detailed Project Report (DPR) and feasibility study rather than with the purchase of machinery.

Quick Answer

A practical business plan for a pharmaceutical manufacturing unit should cover 12 major areas:

1. Product and dosage-form selection
2. Market and business model
3. Regulatory route
4. Manufacturing site
5. Plant layout and GMP design
6. Machinery and utilities
7. Quality-control laboratory
8. Technical manpower
9. Capital investment
10. Working capital
11. Production and sales projections
12. Break-even, profitability and expansion

For a first-time manufacturer, it is generally safer to start with a limited number of non-sterile dosage forms, establish stable production and contract-manufacturing customers, and expand later.

Sterile injections, biologicals, high-potency products, cytotoxics and certain hormonal products require substantially higher technical capability, containment and investment.

Important Regulatory Update for 2026

The Occupational Safety, Health and Working Conditions Code, 2020 came into force on 21 November 2025. Its repeal-and-savings provisions repealed the Factories Act while preserving applicable actions, rules and requirements during transition to the extent they are not inconsistent with the new Code.

Under the OSH Code, a factory generally means premises where manufacturing is carried on with:

• 20 or more workers with the aid of power, or
• 40 or more workers without the aid of power,

subject to state-specific thresholds saved or amended under applicable law. Establishments with 10 or more employees also fall within important registration and health-and-safety provisions.

A pharmaceutical project should therefore check both the current Central Code and the applicable State rules.

Revised Schedule M Is Now the Core GMP Standard

India notified the revised Schedule M through G.S.R. 922(E) dated 28 December 2023.

The revised framework requires a comprehensive Pharmaceutical Quality System incorporating GMP and Quality Risk Management. Senior management is responsible for ensuring that the quality system is adequately resourced and implemented throughout the organisation.

Qualifying manufacturers with turnover up to ₹250 crore could seek an implementation extension, but the extension could not go beyond 31 December 2025. Therefore, a pharmaceutical unit being designed in 2026 should be planned for full revised Schedule M compliance from the beginning.

Step 1: Decide What Type of Pharmaceutical Unit You Want

Before purchasing land or machinery, decide exactly what you will manufacture.

Possible sections include:

Manufacturing section	Examples
Tablets	Plain, coated, dispersible, modified release
Capsules	Hard gelatin or HPMC capsules
Oral liquids	Syrups, suspensions, emulsions
External preparations	Creams, ointments, gels, lotions
Powders	Oral powders, medicated powders
Dry syrups	Antibiotic/non-antibiotic dry suspensions
Small-volume parenterals	Ampoules, vials
Large-volume parenterals	IV fluids
Ophthalmics	Eye drops, eye ointments
Nasal preparations	Nasal drops and sprays
Inhalation products	Inhalers, sprays
APIs	Active pharmaceutical ingredients

Do not attempt to establish every section in the first phase merely because future orders may arise.

Each additional section increases:

• Civil work
• HVAC requirement
• Machinery
• Validation
• Laboratory testing
• Technical staff
• Documentation
• Regulatory inspection
• Working capital

Step 2: Decide Your Business Model

A pharmaceutical manufacturer can generate revenue through several models.

Own Branded Marketing

The company manufactures and sells products under its own brands through:

• Medical representatives
• Distributors
• Stockists
• PCD franchise partners
• Hospitals
• Institutions

This model offers brand ownership but requires a larger sales and marketing budget.

Third-Party Manufacturing

The factory manufactures products for other pharma marketing companies.

The customer generally provides:

• Brand name
• Product requirements
• Artwork
• Purchase order

The manufacturer earns a manufacturing margin.

For a new manufacturing unit, third-party manufacturing can help improve machine utilisation.

Contract Manufacturing

A larger pharmaceutical company may outsource manufacturing under a formal technical and quality agreement.

Revised Schedule M specifically requires outsourced manufacturing and analysis to be clearly defined, agreed and controlled, and the contract giver remains responsible for assessing the competence and suitability of the contract acceptor.

Loan-Licence Manufacturing

Eligible companies may use another manufacturer’s facility under the applicable loan-licence framework.

For drugs other than those in specified Schedule C/C(1)/X categories, loan licences are issued through the applicable Form 25A route.

Institutional Supply

Products can be supplied to:

• Hospitals
• Nursing homes
• Government procurement agencies
• Corporate hospitals
• Institutional distributors

Export Manufacturing

An export-focused factory may build its business around:

• Contract manufacturing
• Generic dossiers
• International tenders
• Country registrations
• WHO-GMP/CoPP markets

Export-oriented projects usually require stronger regulatory documentation and quality systems.

Step 3: Prepare Market Feasibility Study

Before investing, answer:

Which products have demand?

Analyse:

• Product category
• Market size
• Competitors
• Price
• Manufacturing cost
• Batch size
• Raw-material availability
• Product shelf life
• Regulatory difficulty

Who will purchase your products?

Potential customers include:

• Your own marketing division
• PCD companies
• Pharma marketing companies
• Institutional buyers
• Government buyers
• Exporters
• Other manufacturers

What will differentiate your factory?

Possible strengths include:

• Low minimum order quantity
• Fast production
• Export documentation
• Specialized formulations
• WHO-GMP capability
• Flexible packaging
• Development services
• Competitive costing
• Strong quality reputation

Do not base the project solely on the statement that “pharma is profitable.”

Production capacity has no value unless sufficient orders are available.

Step 4: Select the Manufacturing Licence Route

Manufacture and sale of drugs are principally regulated by State Licensing Authorities, while CDSCO handles areas such as new-drug approvals and specified centrally regulated categories.

Common licence routes include:

Activity	Typical application/licence
Drugs other than Schedule C, C(1) and X	Form 24 → Form 25
Loan licence for applicable non-Schedule C/C(1)/X drugs	Form 24A → Form 25A
Schedule C/C(1) drugs, excluding specified categories	Form 27 → Form 28
Certain Schedule C/C(1)/X categories	Applicable Form 27B/28B
LVP, sera, vaccines and specified biologicals	Form 27D → Form 28D

The exact form should be confirmed with the concerned State Licensing Authority and CDSCO because product classification determines the route.

What If You Want to Manufacture a New Drug?

A State manufacturing licence alone is not enough for a drug falling within the definition of a new drug.

Under the New Drugs and Clinical Trials Rules, 2019, a person intending to manufacture a new drug for sale or distribution applies to the Central Licensing Authority in Form CT-21.

Permission for a pharmaceutical formulation may be granted in Form CT-23 after regulatory review.

Therefore, include regulatory-development cost in your business plan if your proposed portfolio contains:

• New drugs
• Certain new fixed-dose combinations
• New indications
• New dosage forms requiring central approval
• Other products covered by NDCT Rules

Different Regulatory Categories Need Different Licences

Do not put every healthcare product into one pharmaceutical manufacturing licence.

Separate regulatory routes apply to categories such as:

Product	Main regulatory route
Allopathic medicines	Drugs and Cosmetics framework
Ayurvedic medicines	AYUSH/ASU drug framework
Nutraceuticals	FSSAI
Cosmetics	Cosmetics Rules
Medical devices	Medical Devices Rules
Veterinary medicines	Drug regulations plus category requirements

Decide the product classification before designing the factory.

Step 5: Select the Location

Location affects both capital cost and long-term operating cost.

Consider:

• Industrial zoning
• Drug-authority acceptability
• Road connectivity
• Airport/cargo access
• Water availability
• Electrical power
• Pollution-control requirements
• Availability of skilled manpower
• Labour cost
• Local pharmaceutical ecosystem
• Transport cost
• Weather and humidity
• Flood risk
• Expansion potential
• Waste disposal
• Fire-service access

Revised Schedule M requires premises to be situated in an environment that, together with protective measures, minimizes contamination risk. It also requires appropriate electrical supply, lighting, temperature, humidity, ventilation and logical flow of materials and personnel.

Industrial Cluster vs Independent Location

Pharmaceutical Cluster

Advantages include:

• Skilled workers
• Machinery suppliers
• Raw-material suppliers
• Contract laboratories
• Transport
• Consultants
• Experienced maintenance engineers

Possible disadvantages include:

• Higher land prices
• More competition for employees
• Higher salary expectations

Low-Cost Industrial Area

Advantages:

• Cheaper land
• Expansion space
• Lower rent

Possible disadvantages:

• Technical manpower shortage
• Higher logistics cost
• Maintenance delays
• Supplier distance

Choose based on total lifecycle cost rather than only land price.

Step 6: Owned vs Rented Premises

Both models are possible subject to regulatory suitability.

Owned Facility

Advantages:

• Long-term control
• Easier permanent modification
• Asset creation
• Expansion freedom

Disadvantages:

• High capital requirement
• Longer setup time
• Land investment does not directly generate production

Rented Facility

Advantages:

• Lower initial capital
• Faster setup
• More working capital remains available

Disadvantages:

• Structural changes require owner approval
• Lease uncertainty
• Relocation risk
• Complex GMP modifications

For rented premises, obtain a sufficiently long lease because pharmaceutical HVAC, epoxy flooring, partitions, utilities and validation cannot be economically shifted every few years.

Step 7: Plant Layout and Design

Plant layout should be designed before civil work begins.

The revised Schedule M requires premises and equipment to minimise:

• Errors
• Contamination
• Cross-contamination
• Dust accumulation
• Mix-ups

It also requires logical material and personnel flow.

A typical flow may be:

Material Receipt → Quarantine → Sampling → QC Approval → Approved Store → Dispensing → Manufacturing → Packing → Finished Goods Quarantine → QA Release → Dispatch

Personnel movement should be separately controlled through:

• Entry
• Change rooms
• Airlocks
• Production corridors
• Exit

Avoid unnecessary crossing of material and personnel routes.

Recommended Manufacturing Areas

The revised Schedule M annexure continues to provide recommended areas for various basic installations.

Section	Recommended basic installation area	Ancillary area
External preparations	30 m²	10 m²
Oral liquids	30 m²	10 m²
Uncoated tablets	60 m²	20 m²
Additional coating section	30 m²	10 m²
Capsules	25 m²	10 m²
Powders	30 m²	Additional room where needed
Ophthalmics	25 m²	10 m²
SVP parenterals	150 m²	100 m²
LVP parenterals	150 m²	150 m²

Schedule M describes these as recommended areas for basic installations. They should not be treated as the total factory area.

A complete factory also requires substantial space for:

• Raw-material warehouse
• Packing-material warehouse
• Sampling
• Dispensing
• Quality Control
• Microbiology
• Stability
• Finished goods
• Utilities
• HVAC
• Change rooms
• Corridors
• Wash areas
• Rejected material
• Returned goods
• Documentation
• Engineering

Therefore, simply adding the Schedule M room minima does not produce a complete project area.

Step 8: Main Areas in a Non-Sterile Pharma Factory

A reasonably planned factory may include:

Warehouse

Separate status areas for:

• Quarantine
• Approved material
• Rejected material
• Returned material
• Printed packaging
• Finished goods

Sampling

Controlled sampling room or booth.

Dispensing

Dedicated weighing and dispensing with dust-control arrangements.

Production

Separate product- and process-specific rooms.

Packaging

Separate primary and secondary packing areas.

Quality Control

Independent from Production.

Microbiology

Where required according to the product portfolio.

Stability

Qualified stability chambers with monitoring and backup.

Engineering

Utility, spare-parts and maintenance control.

QA and Documentation

Controlled documentation and batch-release functions.

Quality-Control Laboratory Must Be Properly Planned

Do not treat the QC laboratory as a small room containing a UV spectrophotometer and balance.

The Drugs Rules require appropriate testing arrangements, and the testing unit should be separate from manufacturing with its head independent from the manufacturing head.

Depending on products, QC may require:

• HPLC
• UV-visible spectrophotometer
• Dissolution tester
• Disintegration tester
• Friability tester
• Hardness tester
• pH meter
• Analytical balances
• Karl Fischer
• Melting-point equipment
• Stability chambers
• Microbiology facilities
• Reference-standard storage
• Retained-sample storage

The licence holder must ensure each batch of raw material and finished product is appropriately tested under the Drugs Rules.

Step 9: Utilities

Utilities are a major project cost and should be designed before machinery selection.

HVAC

The HVAC system may need to control:

• Temperature
• Humidity
• Air filtration
• Pressure differential
• Dust
• Cross-contamination
• Air changes

Revised Schedule M specifically requires design, installation, qualification and maintenance of HVAC systems.

Pharmaceutical Water

Depending on the dosage form, systems may include:

• Potable water
• Purified Water
• Water for Injection
• Clean steam

Compressed Air

Where product-contact compressed air is used, appropriate:

• Filtration
• Drying
• Qualification
• Monitoring

are needed.

Electrical Supply

Plan:

• Connected load
• Transformer
• Generator
• UPS
• Emergency systems
• HVAC backup
• Laboratory backup
• Stability-chamber backup

Other Utilities

May include:

• Boiler
• Chiller
• Cooling tower
• Vacuum system
• Dust extraction
• Nitrogen
• Steam
• Effluent-treatment plant

Step 10: Machinery Selection

Machine capacity should match your projected sales rather than the highest capacity available.

Tablet Section

Typical machinery:

• Sifter
• Mill
• Rapid mixer granulator
• Fluid-bed dryer
• Multi-mill
• Blender
• Tablet compression machine
• Deduster
• Metal detector
• Coating machine
• Blister/strip packing machine

Revised Schedule M specifically recommends separate tablet mixing/granulation/drying, compression and packaging sections and appropriate dust control.

Capsule Section

Typical equipment:

• Sifter
• Blender
• Capsule filling machine
• Capsule polisher
• Metal detector
• Inspection system
• Blister packing machine

Schedule M requires capsule manufacturing in a suitably air-conditioned and dehumidified enclosed area with airlock arrangements.

Liquid Section

Typical machinery:

• Manufacturing vessel
• Sugar syrup vessel
• Storage vessel
• Stirrer
• Homogenizer, where needed
• Colloid mill, where applicable
• Filtration system
• Filling machine
• Capping machine
• Labelling machine

Schedule M recommends closed processing and transfer systems for oral liquids where practical to reduce contamination.

External Preparations

Typical machinery:

• Manufacturing vessel
• Homogenizer
• Vacuum emulsifier
• Colloid mill
• Storage vessel
• Tube filling machine
• Jar filling machine

High-Risk Products Need Special Planning

Do not include penicillins, cytotoxics, certain sex hormones or highly sensitising products in an ordinary multipurpose facility without specialist design.

Revised Schedule M requires dedicated/self-contained approaches for specified high-risk products and places strong emphasis on preventing cross-contamination.

These projects may require:

• Separate building or contained facility
• Separate entrance
• Separate HVAC
• Pressure control
• Dedicated equipment
• Special waste handling
• Personnel protection
• Environmental protection

They should be budgeted as separate projects.

Step 11: Manpower Planning

A typical organization may include:

Department	Typical personnel
Production	Production Head, executives, supervisors, operators
Quality Assurance	QA Head, IPQA, documentation, validation
Quality Control	QC Head, analysts
Microbiology	Microbiologist(s), where required
Warehouse	Warehouse Head, stores officers
Engineering	Engineering Head, HVAC/electrical/mechanical technicians
Regulatory Affairs	Regulatory executive/manager
Purchase	Procurement staff
Planning	Production planning personnel
IT	System/data support
HR/Admin	HR and administration
Safety	EHS/safety personnel as applicable
Dispatch	Logistics team
Finance	Accounts and costing

The Drugs Rules require manufacturing to be conducted under appropriately qualified competent technical staff, and the head of the testing unit must have appropriate qualifications and testing experience acceptable to the Licensing Authority.

Production and QC Should Be Independent

Production should not control finished-product release.

The quality function should have sufficient independence to:

• Approve or reject raw materials
• Approve/reject packaging material
• Review deviations
• Approve specifications
• Review validation
• Approve changes
• Release or reject batches
• Investigate complaints
• Coordinate recalls

Revised Schedule M places senior-management responsibility on maintaining an adequately resourced pharmaceutical quality system.

Step 12: Pharmaceutical Quality System

The business plan should include budget and staff for the Pharmaceutical Quality System.

Major systems include:

• Document control
• Deviation management
• CAPA
• Change control
• Quality Risk Management
• Supplier qualification
• Validation
• Qualification
• Training
• Self-inspection
• Product Quality Review
• Complaints
• Recalls
• Out-of-Specification investigation
• Out-of-Trend investigation
• Data integrity
• Stability
• Calibration
• Preventive maintenance

Quality is an operating cost—not a one-time licensing expense.

Validation Budget

The project budget should separately provide for:

• HVAC qualification
• Water-system qualification
• Equipment qualification
• Process validation
• Cleaning validation
• Analytical-method validation
• Hold-time studies
• Computerised-system validation
• Transport validation, where applicable

Revised Schedule M states that premises, equipment, process systems and facilities affecting product quality must be qualified and validated, and validation must be maintained as an ongoing programme rather than a one-time exercise.

Pharmacovigilance

A 2026 project must also budget for post-market responsibilities.

Revised Schedule M requires the licensee to maintain a pharmacovigilance system for collecting, processing and forwarding adverse-drug-reaction information to licensing authorities.

Therefore, include:

• ADR collection
• Safety-contact details
• Staff training
• Complaint differentiation
• Regulatory reporting
• Safety documentation

CDSCO also issued a specific pharmacovigilance implementation circular in June 2026.

Step 13: Major Regulatory and Business Approvals

Depending on location and activity, a pharmaceutical factory may need:

Approval	Purpose
Company/LLP/firm registration	Legal business entity
Drug manufacturing licence	Pharmaceutical manufacture
Product permissions	Approved products
CT-23, where applicable	New-drug manufacture
OSH/establishment/factory compliance	Worker and factory safety
Pollution Control Board approvals	Environmental compliance
Fire approval	Fire safety
Building/zoning approvals	Industrial use
GST	Tax registration
Electricity sanction	Industrial load
Boiler approval	Where applicable
Groundwater permission	Where applicable
Hazardous-waste authorization	Where applicable
Trademark	Brand protection
IEC	Export

State and local requirements differ, so prepare a regulatory approval matrix before construction starts.

Step 14: How Much Investment Is Required?

There is no reliable single figure for a pharmaceutical plant.

Cost depends on:

• Dosage forms
• Capacity
• Land
• City
• Automation
• HVAC
• Laboratory sophistication
• Sterile/non-sterile production
• Imported/local machinery
• Packaging technology
• Export certification
• Working capital

Main Capital-Expenditure Heads

A proper project budget should include:

Land and Site

• Land
• Registration
• Site development
• Roads
• Drainage
• Boundary
• Security

Civil and GMP Construction

• Building shell
• Cleanable walls
• Epoxy/appropriate flooring
• Ceilings
• GMP partitions
• Doors
• Airlocks
• Change rooms

HVAC

• AHUs
• Ducting
• Filters
• Controls
• Chillers
• Qualification

Utilities

• Water system
• Boiler
• Compressor
• DG set
• Electrical panels
• Transformer
• ETP
• Pumps

Production Machinery

• Manufacturing
• Filling
• Compression
• Coating
• Packaging

Quality Control

• HPLC
• UV
• Dissolution
• Stability
• Microbiology
• Balances
• Other instruments

Warehouse

• Racks
• Pallets
• Temperature monitoring
• Material handling

Digital Systems

• ERP
• LIMS, where adopted
• Backup
• Access controls
• Server infrastructure

Pre-Operational Cost

• Consultants
• Validation
• Training
• Recruitment
• Trial batches
• Licensing
• Product development

A Better Way to Prepare the Capital Budget

Instead of copying market prices from an article, obtain at least:

Three quotations each for major machinery and utility packages.

A planning model for a non-sterile project could allocate capital approximately across the following heads:

Cost head	Illustrative share of fixed project cost
GMP civil/interiors	15–25%
HVAC and utilities	15–25%
Production and packing machinery	25–40%
QC/microbiology/stability	8–15%
Warehouse/IT/material handling	3–8%
Qualification/validation/professional setup	3–8%
Pre-operative expenses/contingency	5–10%

These are planning percentages, not regulatory or market quotations.

Actual values should come from drawings, capacity calculations and vendor quotations.

Working Capital Is Often Underestimated

Many entrepreneurs arrange money for machinery but run short of cash after commissioning.

Working capital may include:

• APIs
• Excipients
• Packing materials
• Printed cartons
• Foils
• Bottles
• Salaries
• Electricity
• Fuel
• Laboratory consumables
• Reference standards
• Maintenance
• Freight
• Credit to customers
• GST timing
• Product development
• Stability batches
• Expiry/rejection provision

A third-party manufacturing business may also need to give customers 30–90 days’ credit while raw-material suppliers demand shorter payment terms.

Working Capital Formula

A basic estimate can be prepared as:

Working Capital = Raw Material Inventory + Packing Inventory + WIP + Finished Goods + Receivables + Cash Requirement − Supplier Credit

Prepare the calculation product-wise rather than using a random percentage of machinery cost.

Step 15: Production Capacity

Machine catalogue capacity is not equal to practical saleable capacity.

For example:

Theoretical Capacity = Machine Output × Operating Hours × Working Days

Then reduce this for:

• Cleaning
• Changeover
• Breakdown
• Validation
• Maintenance
• Rejections
• Batch change
• Market demand

A more realistic calculation is:

Saleable Capacity = Rated Capacity × Utilisation × Yield

A new factory should not prepare its bank projections assuming 100% capacity utilisation from the first year.

Illustrative Capacity Ramp-Up

A conservative business model may use an assumption such as:

Year	Illustrative capacity utilisation
Year 1	25–40%
Year 2	40–55%
Year 3	55–70%
Year 4 onward	Based on actual order book

These are project-planning assumptions only.

A bankable report should justify them using letters of intent, existing sales, contract enquiries and market analysis.

Product Costing

Manufacturing cost per product should include:

Raw Material + Packing Material + Direct Labour + Utilities + Testing + Manufacturing Overhead + QA/QC Cost + Rejection Provision + Depreciation Allocation + Finance Cost

For third-party manufacturing, also consider:

• Artwork
• Changeover
• Low batch size
• Special testing
• Stability
• Development
• Documentation
• Freight
• Credit period

A product can show a manufacturing profit on paper but still lose money if batch size is too small.

Contribution Margin

To evaluate profitability:

Contribution = Net Selling Price − Variable Cost

Contribution must cover:

• Salaries
• Rent
• Interest
• Depreciation
• Administration
• QA overhead
• Regulatory overhead

before the plant earns profit.

Break-Even Calculation

Suppose a factory has:

• Monthly fixed operating expenses = ₹25 lakh
• Variable costs = 65% of net sales
• Contribution margin = 35%

Then:

Break-Even Monthly Sales = ₹25 lakh ÷ 35%

= approximately ₹71.4 lakh per month

Annualised:

= approximately ₹8.57 crore net sales

This is only an illustration, but it shows why the plant’s order pipeline matters as much as machinery capacity.

Revenue Planning

Prepare separate projections for:

• Own-brand sales
• Third-party manufacturing
• Loan-licence work
• Institutional supply
• Export
• Contract manufacturing

Avoid depending on only one large customer.

A customer contributing 60–70% of plant sales creates significant business risk.

Gross Margin vs Net Profit

Do not call the difference between selling price and raw-material cost “profit.”

Net profit should account for:

• Salaries
• Electricity
• HVAC
• QC
• QA
• Validation
• Maintenance
• Depreciation
• Finance cost
• Marketing
• Expiry
• Rejects
• Returns
• Regulatory cost
• Tax

Step 16: Prepare a Sales Plan Before Commissioning

A manufacturing project should build customers during construction.

Potential activities include:

• Third-party manufacturing enquiries
• PCD companies
• Institutional registrations
• Export enquiries
• Own-brand distributor appointment
• Product catalogue development
• Trade exhibitions
• Company website
• B2B marketing

Do not wait until the factory receives its licence to begin looking for customers.

Step 17: Application and Inspection

A practical licensing sequence is:

1. Finalize product/dosage-form scope.
2. Select industrial site.
3. Prepare GMP layout.
4. Complete required industrial approvals.
5. Construct the facility.
6. Install HVAC and utilities.
7. Install machinery.
8. Establish QC laboratory.
9. Recruit approved technical staff.
10. Prepare SOPs and quality systems.
11. Complete qualification.
12. Submit manufacturing-licence application.
13. Complete Drug Inspector/regulatory inspection.
14. Correct observations.
15. Obtain manufacturing licence.
16. Obtain individual product permissions.
17. Conduct applicable validation batches.
18. Begin commercial manufacture after required approvals.

Do not manufacture commercial batches simply because the machinery installation is complete.

Inspection Readiness

Before regulatory inspection, perform an internal GMP audit covering:

• Premises
• Material flow
• Personnel flow
• HVAC
• Water
• Equipment
• Calibration
• Qualification
• SOPs
• QC
• Documentation
• Technical staff
• Warehouses
• Cleaning
• Pest control
• Safety
• Computer systems
• Data integrity

Worker Safety

Pharmaceutical facilities may expose workers to:

• Dust
• Solvents
• Potent APIs
• Noise
• Moving machinery
• Heat
• Chemicals
• Compressed gases

Provide appropriate:

• PPE
• Local exhaust
• Dust extraction
• Machine guards
• Safety training
• First aid
• Emergency response
• Fire safety
• Spill management

Worker safety planning must now be aligned with the Occupational Safety, Health and Working Conditions Code and applicable state requirements.

Recommended First-Time Manufacturing Strategy

A first-time manufacturer should consider starting with a manageable portfolio such as:

Option A: Tablets + capsules

or

Option B: Oral liquids + external preparations

or

Option C: One focused dosage form with third-party manufacturing specialization.

Avoid beginning simultaneously with:

• Tablets
• Capsules
• Syrups
• Injectables
• Ophthalmics
• Hormones
• Penicillins

unless the project has significant capital, specialist management and confirmed commercial demand.

Sterile Manufacturing Requires a Separate Business Case

A sterile injectable project requires:

• Cleanrooms
• Classified HVAC
• WFI
• Clean steam
• Autoclaves
• Depyrogenation
• Aseptic filling
• Environmental monitoring
• Media fills
• Microbiology
• Sterility testing
• Endotoxin testing

Schedule M recommends 150 m² basic plus 100 m² ancillary space for Small Volume Injectables and 150 m² plus 150 m² for Large Volume Parenterals, before considering many other support areas.

Therefore, injectable plants should not be financially compared with simple non-sterile units.

Typical Implementation Schedule

An indicative non-sterile project schedule may look like:

Phase	Approximate planning period
Feasibility and DPR	1–2 months
Site and concept design	1–3 months
Detailed GMP engineering	2–4 months
Construction	4–8 months
Machinery procurement	Parallel, often 3–8 months
HVAC/utilities installation	2–4 months
Qualification and documentation	2–4 months
Inspection and licence processing	Depends on authority and compliance

Activities overlap, so total time is not simply the sum of each row.

A relatively straightforward non-sterile project may still require approximately a year or more from concept to commercial readiness. Complex sterile projects may take considerably longer.

No fixed regulatory approval timeline should be promised in the business plan.

Project Risk Analysis

A DPR should identify at least these risks:

Risk	Control
Low capacity utilisation	Secure customers before commissioning
Cost overrun	Fixed quotations and contingency
Licence delay	Early regulatory review
HVAC failure	Good engineering and preventive maintenance
Product failure	Development and validation
Customer credit	Credit controls
Raw-material price fluctuation	Multiple approved vendors
Skilled manpower shortage	Select suitable location
Regulatory changes	Regulatory affairs function
Data-integrity issue	Controlled systems and training
Excessive product range	Phase-wise expansion
Cross-contamination	Risk-based facility design

Bankable DPR Structure

A Detailed Project Report should include:

1. Executive summary
2. Promoter profile
3. Business background
4. Product list
5. Dosage forms
6. Manufacturing capacity
7. Market analysis
8. Competition
9. Regulatory strategy
10. Site details
11. Plant layout
12. Machinery
13. Utilities
14. Quality-control laboratory
15. Manpower
16. Raw materials
17. Packaging
18. Manufacturing process
19. Environmental and safety compliance
20. Project implementation schedule
21. Fixed capital
22. Working capital
23. Sales projections
24. Cost of production
25. Profit and loss projections
26. Cash-flow statement
27. Break-even analysis
28. Debt-service coverage
29. Sensitivity analysis
30. Risk analysis

Financial Projections Should Cover At least Five Years

The DPR should preferably show:

Financial statement	Why required
Project cost	Capital requirement
Means of finance	Promoter equity/loan
Working capital	Operational funding
Sales projection	Revenue
Cost of goods	Gross profitability
Profit and loss	Earnings
Cash flow	Liquidity
Balance sheet	Financial position
Break-even	Minimum required sales
DSCR	Loan repayment ability
Sensitivity analysis	Downside risk

Sensitivity Analysis

Calculate what happens when:

• Sales are 20% below projection.
• Raw material cost rises 10%.
• Plant commissioning is delayed six months.
• Customer credit increases.
• Interest rate rises.
• Capacity utilisation remains low.
• One major customer leaves.

A project that is profitable only at 90% capacity utilisation is risky.

Common Mistakes in Pharma Manufacturing Projects

Avoid:

• Buying machinery before finalising the layout
• Buying land without checking industrial suitability
• Designing from old Schedule M drawings
• Using outdated machinery-price estimates
• Underestimating HVAC
• Underestimating QC laboratory cost
• Ignoring working capital
• Planning at 100% capacity
• Starting too many dosage forms
• Hiring technical staff only before inspection
• Copying SOPs
• Ignoring validation
• Treating GMP as a one-time certificate
• Mixing high-risk products in a general facility
• Ignoring pharmacovigilance
• Ignoring data integrity
• Depending on one customer
• Constructing before regulatory consultation

Practical Pre-Investment Checklist

Before committing major capital, confirm:

• Product list finalised
• Regulatory categories checked
• Dosage forms selected
• Market study completed
• Proposed customers identified
• Batch sizes decided
• Capacity calculated
• Site zoning checked
• Pollution requirements checked
• GMP architect appointed
• Layout reviewed
• Utilities calculated
• Three machinery quotations obtained
• Three HVAC quotations obtained
• QC equipment planned
• Technical manpower budgeted
• Working capital calculated
• Regulatory route confirmed
• Five-year sales forecast prepared
• Break-even calculated
• Downside scenario tested

Final Answer

A pharmaceutical manufacturing business plan in India should not begin with the question:

“How much does a tablet machine cost?”

It should begin with:

“Which products will we manufacture, for whom, at what capacity, under which licence, with what investment, and at what break-even sales level?”

For a 2026 project, the most important requirements are:

• Full revised Schedule M planning
• Pharmaceutical Quality System
• Quality Risk Management
• Appropriate manufacturing licence
• Qualified technical personnel
• Risk-based plant layout
• Validated HVAC and utilities
• Strong Quality Control and Quality Assurance
• Qualification and validation
• Pharmacovigilance and recall systems
• Adequate working capital
• Confirmed market demand

The revised Schedule M has made it particularly important to budget for quality systems rather than only buildings and production machines.

A first-time manufacturer should normally begin with a focused non-sterile product portfolio and expand after achieving stable quality, capacity utilisation and customer demand.

Frequently Asked Questions

1. How much investment is required to start a pharmaceutical manufacturing unit?

There is no fixed amount. Investment depends heavily on dosage forms, capacity, automation, HVAC, laboratory requirements, land and whether production is sterile or non-sterile.

2. Can a pharma factory be started in rented premises?

Yes, subject to premises suitability, industrial-use permission, lease terms and regulatory acceptance.

3. Is the Factories Act still the main factory law?

The OSHWC Code, 2020 came into force on 21 November 2025 and repealed the Factories Act subject to savings and transitional provisions. State-specific requirements must also be checked.

4. Is revised Schedule M compulsory for a new plant?

A new plant being established in 2026 should be designed for revised Schedule M compliance from the beginning.

5. What licence is required for tablets and ordinary oral liquids?

Drugs other than those falling under specified Schedule C/C(1)/X categories are generally manufactured under the Form 25 licensing route, subject to the exact product classification.

6. Can the same plant manufacture tablets, capsules and syrups?

Yes, if the appropriate sections, licence, machinery, utilities, technical staff and GMP controls are approved.

7. Can penicillin be manufactured in a normal tablet section?

Special segregation and dedicated/self-contained arrangements apply to highly sensitising products such as penicillins.

8. Is a QC laboratory compulsory?

Adequate batch-testing arrangements are compulsory, and manufacturing facilities require proper quality-control capability under the Drugs Rules.

9. Is one manufacturing chemist and one analytical chemist enough?

Those may satisfy only part of the legal technical-staff structure. A modern plant normally also needs QA, production supervisors, engineering, warehouse, regulatory and other support functions.

10. Does each product need separate approval?

The manufacturing licence covers approved categories and products. Individual product permissions and, where applicable, central new-drug approvals must also be obtained.

11. Can I manufacture a new drug immediately after obtaining Form 25?

No. Where the product is a new drug, Central Licensing Authority permission under the NDCT Rules may be required before manufacture for sale or distribution.

12. Is third-party manufacturing useful for a new plant?

Yes. It can improve capacity utilisation and diversify revenue, provided sufficient compliant customers and contracts are available.

13. What is the biggest hidden cost in a pharma project?

Commonly underestimated costs include HVAC, utilities, Quality Control, validation, working capital, technical staff and regulatory documentation.

14. How is break-even calculated?

Break-even sales equal total fixed costs divided by the contribution-margin ratio.

15. Which dosage form is best for a new manufacturer?

There is no universal choice. Non-sterile tablets, capsules, oral liquids or external preparations are generally simpler than sterile injectables or high-containment products, but the best option depends on demand and technical capability.

Looking for Ayurvedic Franchise or Distribution Opportunities?

Elzac Herbal India offers opportunities for entrepreneurs interested in Ayurvedic and herbal product distribution, franchise marketing and third-party manufacturing.

Elzac Herbal India offers:

• Ayurvedic & Herbal Product Range
• Franchise & Distribution Opportunities
• Third-Party Manufacturing
• Product Development Support
• Marketing Guidance
• PAN India Business Opportunities

Whether you are an entrepreneur, retailer, distributor, or healthcare professional, our team can help you explore the right business opportunity in the growing Ayurvedic sector.

Contact us today to discuss ayurvedic franchise, distribution, or third-party manufacturing opportunities.